LV11882B - AMINOTETRALINE DERIVATIVES FOR TREATMENT OF CIRCULAR AND HUMAN DISEASES - Google Patents

AMINOTETRALINE DERIVATIVES FOR TREATMENT OF CIRCULAR AND HUMAN DISEASES Download PDF

Info

Publication number
LV11882B
LV11882B LVP-97-166A LV970166A LV11882B LV 11882 B LV11882 B LV 11882B LV 970166 A LV970166 A LV 970166A LV 11882 B LV11882 B LV 11882B
Authority
LV
Latvia
Prior art keywords
chf
heart failure
therapy
methylaminotetralin
pharmaceutical compositions
Prior art date
Application number
LVP-97-166A
Other languages
English (en)
Latvian (lv)
Other versions
LV11882A (lv
Inventor
Paolo Chiesi
Stefano Bongrani
Roberta Razzetti
Maurizio Civelli
Alberto Umile
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of LV11882A publication Critical patent/LV11882A/xx
Publication of LV11882B publication Critical patent/LV11882B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LVP-97-166A 1995-03-17 1997-09-15 AMINOTETRALINE DERIVATIVES FOR TREATMENT OF CIRCULAR AND HUMAN DISEASES LV11882B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95MI000532A IT1275935B1 (it) 1995-03-17 1995-03-17 Derivato di aminotetralina per la terapia di malattie cardiovascolari
PCT/EP1996/001060 WO1996029065A2 (en) 1995-03-17 1996-03-13 Aminotetralin derivative for the therapy of cardiovascular diseases

Publications (2)

Publication Number Publication Date
LV11882A LV11882A (lv) 1997-12-20
LV11882B true LV11882B (en) 1998-03-20

Family

ID=11370947

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-97-166A LV11882B (en) 1995-03-17 1997-09-15 AMINOTETRALINE DERIVATIVES FOR TREATMENT OF CIRCULAR AND HUMAN DISEASES

Country Status (31)

Country Link
US (2) US6013678A (et)
EP (2) EP0814791B1 (et)
JP (1) JPH11502211A (et)
KR (1) KR100391143B1 (et)
CN (1) CN1112920C (et)
AT (1) ATE218856T1 (et)
AU (1) AU702656B2 (et)
BR (1) BR9607996A (et)
CA (1) CA2215671A1 (et)
CZ (1) CZ288488B6 (et)
DE (1) DE69621786T2 (et)
DK (1) DK0814791T3 (et)
EA (1) EA000937B1 (et)
EE (1) EE04040B1 (et)
ES (1) ES2177769T3 (et)
HK (2) HK1004802A1 (et)
HU (1) HUP9801686A3 (et)
IL (1) IL117518A (et)
IT (1) IT1275935B1 (et)
LT (1) LT4355B (et)
LV (1) LV11882B (et)
MX (1) MX9706971A (et)
NO (1) NO317402B1 (et)
NZ (1) NZ303993A (et)
PL (1) PL183347B1 (et)
PT (1) PT814791E (et)
SI (1) SI9620036B (et)
SK (1) SK282952B6 (et)
TR (1) TR199700963T1 (et)
WO (1) WO1996029065A2 (et)
ZA (1) ZA962073B (et)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2695157B2 (ja) * 1986-12-29 1997-12-24 松下電器産業株式会社 可変パイプラインプロセッサ
WO2000076544A1 (en) * 1996-03-13 2000-12-21 Chiesi Farmaceutici S.P.A. Aminotetralin derivative for the therapy of cardiovascular diseases
SI1183046T1 (en) * 1999-06-09 2004-02-29 Chiesi Farmaceutici S.P.A. Aminotetralin derivative for the therapy of cardiovascular diseases
MXPA01012638A (es) * 1999-06-09 2002-07-22 Chiesi Farma Spa Derivados de aminotetralina para la terapia de enfermedades cardiovasculares.
IT1313583B1 (it) * 1999-07-30 2002-09-09 Chiesi Farma Spa Derivati 2-amminotetralinici per la terapia del glaucoma.
IL152751A0 (en) * 2000-05-12 2003-06-24 Chiesi Farma Spa Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
SE0101854L (sv) * 2001-05-28 2002-11-29 Bioneris Ab Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
EP1384708A1 (en) * 2002-07-26 2004-01-28 CHIESI FARMACEUTICI S.p.A. Process for the manufacture of form I of nolomirole hydrochloride
US20050101668A1 (en) * 2003-07-24 2005-05-12 Chiesi Farmaceutici S.P.A. Aminotetralin derivatives as a medicament for the treatment and prevention of myocardial ischemic conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134997A (en) * 1977-03-01 1979-01-16 University Of Iowa Research Foundation Effect of an aminotetralin derivative on coronary blood flow in infarcted hearts
SU998342A1 (ru) 1981-12-11 1983-02-23 Предприятие П/Я А-3732 Способ получени синтетического цеолита типа @
IT1218322B (it) * 1982-06-10 1990-04-12 Chiesi Farma Spa Derivati di 1,2,3,4-tetraidronaftalene,procedimento di preparazione e relative composizioni farmaceutiche

Also Published As

Publication number Publication date
LT4355B (lt) 1998-06-25
PL183347B1 (pl) 2002-06-28
DK0814791T3 (da) 2002-10-07
DE69621786D1 (de) 2002-07-18
EP0814791A1 (en) 1998-01-07
EP0814791B1 (en) 2002-06-12
LT97147A (en) 1998-02-25
ATE218856T1 (de) 2002-06-15
TR199700963T1 (xx) 1998-02-21
EE9700231A (et) 1998-04-15
HUP9801686A3 (en) 1999-10-28
ZA962073B (en) 1996-11-27
SK125497A3 (en) 1998-02-04
US6103760A (en) 2000-08-15
CZ286697A3 (cs) 1998-03-18
CZ288488B6 (en) 2001-06-13
CA2215671A1 (en) 1996-09-26
WO1996029065A2 (en) 1996-09-26
KR100391143B1 (ko) 2003-11-28
EA199700243A1 (ru) 1998-02-26
EE04040B1 (et) 2003-06-16
NZ303993A (en) 2000-12-22
NO974267L (no) 1997-11-07
ITMI950532A0 (it) 1995-03-17
SK282952B6 (sk) 2003-01-09
SI9620036A (sl) 1998-02-28
PL322284A1 (en) 1998-01-19
SI9620036B (sl) 2002-10-31
ES2177769T3 (es) 2002-12-16
ITMI950532A1 (it) 1996-09-17
IL117518A (en) 2001-05-20
IT1275935B1 (it) 1997-10-24
BR9607996A (pt) 1998-06-23
HK1004802A1 (en) 1998-12-11
JPH11502211A (ja) 1999-02-23
AU5107296A (en) 1996-10-08
EP1216702A2 (en) 2002-06-26
CN1181699A (zh) 1998-05-13
PT814791E (pt) 2002-10-31
WO1996029065A3 (en) 1996-11-28
DE69621786T2 (de) 2003-01-02
NO974267D0 (no) 1997-09-16
NO317402B1 (no) 2004-10-25
KR19980703030A (ko) 1998-09-05
MX9706971A (es) 1997-11-29
CN1112920C (zh) 2003-07-02
AU702656B2 (en) 1999-02-25
HK1048060A1 (zh) 2003-03-21
LV11882A (lv) 1997-12-20
HUP9801686A2 (hu) 1999-06-28
US6013678A (en) 2000-01-11
IL117518A0 (en) 1996-07-23
EA000937B1 (ru) 2000-06-26
EP1216702A3 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
Kurien et al. The role of free fatty acids in the production of ventricular arrhythmias after acute coronary artery occlusion
MacCarthy et al. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects
Hollister The effect of adrenergic blocking agents (including chlorpromazine) on serum lipid levels of patients with disorders of fat metabolism
Wilson et al. Effects of an orally administered prostaglandin analogue (16, 16-dimethyl prostaglandin E2) on human gastric secretion
EP0814791B1 (en) Aminotetralin derivative for the therapy of cardiovascular diseases
Liard L-NAME antagonizes vasopressin V2-induced vasodilatation in dogs
Nakano Cardiovascular actions of vasopressin
EP1183046B1 (en) Aminotetralin derivative for the therapy of cardiovascular diseases
WO2000076544A1 (en) Aminotetralin derivative for the therapy of cardiovascular diseases
EP1331004A2 (en) Aminotetralin Derivative for the Therapy of Cardiovascular Diseases
Aronson et al. Effects of fenoldopam on renal blood flow and systemic hemodynamics during isoilurane anesthesia
Noguchi et al. Effects of nipradilol on myocardial ischaemia produced by coronary stenosis in dogs.
Prichard β-adrenoceptor blocking agents
Atkins Alcohol and the heart